Key result
Seven endocrine-metabolic axes drive HFpEF myocardial fibrosis, supporting phenotype-guided antifibrotic therapy.
Why the study?
Myocardial fibrosis in HFpEF is increasingly recognized as an actively regulated process shaped by endocrine and metabolic signals rather than merely a passive haemodynamic consequence.
This review provides an endocrine framework for understanding cardiac fibrosis in HFpEF, advocating for phenotype-guided antifibrotic strategies targeting specific hormonal axes.
Answers are grounded in this paper and cite their sources.
May inform endocrine-targeted HFpEF trials; leaves open whether axis-specific therapies alter fibrosis or outcomes.
Heart failure with preserved ejection fraction (HFpEF) is a dominant heart failure phenotype in ageing populations and commonly develops on a background of hypertension, obesity, diabetes, and systemic inflammation. Myocardial fibrosis is a central structural lesion in HFpEF, but it is increasingly recognised not merely as a passive haemodynamic consequence but as an actively regulated process shaped by endocrine and metabolic signals. This review examines seven interacting hormonal axes, namely the renin-angiotensin-aldosterone system, tissue-amplified glucocorticoid signalling via 11β-HSD1, gonadal steroid deficiency, adipokine dysregulation and epicardial adipose tissue inflammation, insulin resistance, altered thyroid hormone signalling, and disordered mineral metabolism, which converge on shared profibrotic effectors, including TGF-β-Smad signalling, NADPH oxidase-derived oxidative stress, suppression of the NO-cGMP-PKG pathway, and mTOR-AMPK-FOXO dysregulation. These axes interact via self-reinforcing feedback circuits and converge on coronary microvascular dysfunction as a central pathological node, helping to explain the heterogeneity of HFpEF, its female predominance, and incomplete responses to single-pathway therapies. We distinguish clinically validated endocrine-modulating strategies, including SGLT2 inhibitors, mineralocorticoid receptor antagonism, and incretin-based therapy in selected phenotypes, from emerging tissue-targeted approaches. This endocrine framework provides a basis for phenotype-guided antifibrotic strategies in HFpEF.
No takes yet. Share an insight, caveat, or question.
Chaturvedi et al. (2026) conducted a review in Heart failure with preserved ejection fraction (HFpEF). Endocrine-modulating strategies was evaluated. Myocardial fibrosis in HFpEF is actively regulated by seven interacting endocrine and metabolic axes, providing a pathophysiological framework for phenotype-guided antifibrotic strategies.
Synapse has enriched 10 related papers. Consider them for comparative context: